Prevacid's decline drags down Takeda
This article was originally published in Scrip
Executive Summary
Sharply lower US sales of Prevacid (lansoprazole) following the loss of exclusivity, together with the strength of the yen, both hurt Takeda in the nine months to 31 December, when net sales at Japan's largest pharma company slid by 4% to ¥1,081.1 billion ($13.26 billion).